Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies

被引:26
作者
Becker, KF
Kremmer, E
Eulitz, M
Schulz, S
Mages, J
Handschuh, G
Wheelock, MJ
Cleton-Jansen, AM
Höfler, H
Becker, I
机构
[1] Tech Univ, Klinikum Isar, Inst Pathol, D-81675 Munich, Germany
[2] GSF Forschungszentrum Umwelt & Gesundheit, Inst Pathol, D-85764 Neuherberg, Germany
[3] GSF Forschungszentrum Umwelt & Gesundheit, Inst Immunol, D-85764 Neuherberg, Germany
[4] GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Molekularbiol, D-85764 Neuherberg, Germany
[5] Univ Nebraska, Med Ctr, Dept Oral Biol, Omaha, NE 68198 USA
[6] Univ Nebraska, Med Ctr, Eppley Res Inst, Omaha, NE 68198 USA
[7] Leiden Univ, Ctr Med, Dept Pathol, NL-2300 RC Leiden, Netherlands
[8] Leiden Univ, Ctr Med, Dept Human Genet, NL-2300 RC Leiden, Netherlands
关键词
gene mutation; gastric cancer; breast cancer; immunohistochemistry;
D O I
10.1002/path.1149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunohistochemical analysis has been used to show that expression of the homophilic cell-to-cell adhesion molecule, E-cadherin, is frequently altered in human cancers, including gastric and breast carcinoma. Besides genetic down-regulation, structural mutations such as in-frame deletions of exon 8 and exon 9 were frequently found; these may affect the binding of monoclonal antibodies used for immunohistochemical analysis. In this study it was found that antibodies HECD-1 and E9, two monoclonal antibodies often used in E-cadherin immunoanalysis, react with epitopes present at least in part in exon 8 and exon 9, respectively. This study generated and characterized a mutation-specific monoclonal antibody, E-cad delta 8-1, reacting with the mutant protein lacking exon 8 but not with the wild-type molecule. By using E-cad delta 8-1 and HECD-1, it was possible separately to analyse the immunoreactivity of mutant and normal E-cadherin proteins, respectively, in an allele-specific manner in archival material. A similar analysis was performed using E9 and the previously characterized mutation-specific antibody E-cad delta 9-1. Typically, in gastric and breast cancer harbouring E-cadherin splice site gene mutations, the mutant proteins were expressed but the wild-type protein was not detected in malignant tissues. These results indicate that variant-specific monoclonal antibodies can be used to identify differentially expressed E-cadherin proteins. For immunohistochemical analysis of E-cadherin, at least two different monoclonal antibodies should be used to exclude alterations of the epitopes resulting in failure to detect a mutant protein. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 37 条
[1]   Integration of endoplasmic reticulum signaling in health and disease [J].
Aridor, M ;
Balch, WE .
NATURE MEDICINE, 1999, 5 (07) :745-751
[2]   The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells [J].
Batlle, E ;
Sancho, E ;
Franci, C ;
Domínguez, D ;
Monfar, M ;
Baulida, J ;
de Herreros, AG .
NATURE CELL BIOLOGY, 2000, 2 (02) :84-89
[3]  
BECKER KF, 1994, CANCER RES, V54, P3845
[4]   Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody [J].
Becker, KF ;
Kremmer, E ;
Eulitz, M ;
Becker, I ;
Handschuh, G ;
Schuhmacher, C ;
Müller, W ;
Gabbert, HE ;
Ochiai, A ;
Hirohashi, S ;
Höfler, H .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1803-1809
[5]  
Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO
[6]  
2-D
[7]  
Berx G, 1996, ONCOGENE, V13, P1919
[8]   Roles for Nkx3.1 in prostate development and cancer [J].
Bhatia-Gaur, R ;
Donjacour, AA ;
Sciavolino, PJ ;
Kim, M ;
Desai, N ;
Young, P ;
Norton, CR ;
Gridley, T ;
Cardiff, RD ;
Cunha, GR ;
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 1999, 13 (08) :966-977
[9]   CADHERIN EXPRESSION IN CARCINOMAS - ROLE IN THE FORMATION OF CELL-JUNCTIONS AND THE PREVENTION OF INVASIVENESS [J].
BIRCHMEIER, W ;
BEHRENS, J .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (01) :11-26
[10]  
Caldas C, 1999, J MED GENET, V36, P873